Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin pre-treatment in PCI (TIPS-3)
NCT01378715Phase 3
Key facts
- Status
- Unknown
- Start
- Jun 2010
- Primary completion
- Jun 2012
- Countries
- 2
- Sponsor
- Motol University Hospital
- Modality
- Orthosteric Ligands
- Drugs
- rosuvastatin
- Conditions
- coronary artery disease (CAD)
01
Overview
Phase 3, randomised, open-label trial of rosuvastatin in coronary artery disease (CAD), sponsored by Motol University Hospital. Primary endpoint: Periprocedural myocardial infarction (TnI ≥ 1.5x ULN) at 24 hours. Status: unknown.
02
Design
- Study design
- RandomizedOpen-label
03
Who it enrols
Patients with significant coronary artery stenosis or occlusion indicated for PCI, with negative troponin I and no chronic high-dose rosuvastatin use.
04
Endpoints
Primary
Periprocedural myocardial infarction (TnI ≥ 1.5x ULN)
Secondary
Periprocedural myocardial infarction (TnI ≥ 3x ULN)
Beyond the preview
Go deeper on NCT01378715.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01378715.